Skip to content

Clinical trials

Observational Tuberculosis trials in India

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Tuberculosis Phase: Observational Country / region: India Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20061
20071
20081
20092
20101
20121
20131
20161
20171
20181
20196
20202
20211

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17
Unknown status2
Recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
All India Institute of Medical Sciences3
National Institute of Allergy and Infectious Diseases (NIAID)3
Foundation for Innovative New Diagnostics, Switzerland2
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1
BioMérieux1
Elizabeth Glaser Pediatric AIDS Foundation1
Harvard School of Public Health (HSPH)1
Michael Hoelscher1
Ministry of Science and Technology, India1
Post Graduate Institute of Medical Education and Research, Chandigarh1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Tuberculosis21
Latent Tuberculosis4
HIV Infections3
Tuberculosis, Multidrug-Resistant3
Cryptococcosis2
Extensively Drug-Resistant Tuberculosis2
Hepatitis2
Malnutrition2
Opportunistic Infections2
Acquired Immunodeficiency Syndrome1

Trials

Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.